LEADER 05704nam 2201201z- 450 001 9910367757003321 005 20231214133146.0 010 $a3-03921-153-6 035 $a(CKB)4100000010106147 035 $a(oapen)https://directory.doabooks.org/handle/20.500.12854/56626 035 $a(EXLCZ)994100000010106147 100 $a20202102d2019 |y 0 101 0 $aeng 135 $aurmn|---annan 181 $ctxt$2rdacontent 182 $cc$2rdamedia 183 $acr$2rdacarrier 200 10$aPolyamine Metabolism in Disease and Polyamine-Targeted Therapies 210 $cMDPI - Multidisciplinary Digital Publishing Institute$d2019 215 $a1 electronic resource (240 p.) 311 $a3-03921-152-8 330 $aPolyamines are ubiquitous polycations essential for all cellular life. The most common polyamines in eukaryotes, spermine, spermidine, and putrescine, exist in millimolar intracellular concentrations that are tightly regulated through biosynthesis, catabolism, and transport. Polyamines interact with, and regulate, negatively charged macromolecules, including nucleic acids, proteins, and ion channels. Accordingly, alterations in polyamine metabolism affect cellular proliferation and survival through changes in gene expression and transcription, translation, autophagy, oxidative stress, and apoptosis. Dysregulation of these multifaceted polyamine functions contribute to multiple disease processes, thus their metabolism and function have been targeted for preventive or therapeutic intervention. The correlation between elevated polyamine levels and cancer is well established, and ornithine decarboxylase, the rate-limiting biosynthetic enzyme in the production of putrescine, is a bona fide transcriptional target of the Myc oncogene. Furthermore, induced polyamine catabolism contributes to carcinogenesis that is associated with certain forms of chronic infection and/or inflammation through the production of reactive oxygen species. These and other characteristics specific to cancer cells have led to the development of polyamine-based agents and inhibitors aimed at exploiting the polyamine metabolic pathway for chemotherapeutic and chemopreventive benefit. In addition to cancer, polyamines are involved in the pathologies of neurodegenerative diseases including Alzheimer?s and Parkinson?s, parasitic and infectious diseases, wound healing, ischemia/reperfusion injuries, and certain age-related conditions, as polyamines are known to decrease with age. As in cancer, polyamine-based therapies for these conditions are an area of active investigation. With recent advances in immunotherapy, interest has increased regarding polyamine-associated modulation of immune responses, as well as potential immunoregulation of polyamine metabolism, the results of which could have relevance to multiple disease processes. The goal of this Special Issue of Medical Sciences is to present the most recent advances in polyamine research as it relates to health, disease, and/or therapy. 610 $aprotein synthesis in cancer 610 $aneuroblastoma 610 $aepigenetics 610 $aDrosophila imaginal discs 610 $apneumococcal pneumonia 610 $atransgenic mice 610 $aspermidine/spermine N1-acetyl transferase 610 $a?-difluoromethylornithine 610 $aMYC 610 $askeletal muscle 610 $aprotein expression 610 $acurcumin 610 $acolorectal cancer 610 $aautophagy 610 $ahuman embryonic kidney 293 (HEK293) 610 $amelanoma 610 $atumor immunity 610 $aSnyder-Robinson Syndrome 610 $aStreptococcus pneumoniae 610 $aB-lymphocytes 610 $aautoimmunity 610 $aspermine oxidase 610 $acell differentiation 610 $adiferuloylmethane 610 $aimmunity 610 $aantizyme 610 $atransgenic mouse 610 $apolyamine 610 $ahirsutism 610 $achemoprevention 610 $aCRISPR 610 $atransglutaminase 610 $apolyamine analogs 610 $aNF-?B 610 $aspermine synthase 610 $aatrophy 610 $aaging 610 $aoxidative stress 610 $amast cells 610 $aAfrican sleeping sickness 610 $apancreatic ductal adenocarcinoma 610 $aeflornithine 610 $acarcinogenesis 610 $aornithine decarboxylase 610 $apolyamine transport inhibitor 610 $aputrescine 610 $aneutrophils 610 $aspermidine 610 $auntranslated region 610 $aspermine 610 $apolyphenol 610 $aM2 macrophages 610 $apolyamine transport system 610 $ametabolism 610 $adifluoromethylorthinine 610 $aDFMO 610 $aantizyme inhibitors 610 $acapsule 610 $apolyamine transport 610 $aeosinophils 610 $aMCF-7 cells 610 $adifluoromethylornithine 610 $apolyamine metabolism 610 $amutant BRAF 610 $apolyamines 610 $acadaverine 610 $aproteomics 610 $aairway smooth muscle cells 610 $abreast cancer 610 $aX-linked intellectual disability 610 $acomplementation 610 $aT-lymphocytes 610 $abis(ethyl)polyamine analogs 610 $aantizyme 1 610 $acancer 610 $aosteosarcoma 700 $aMurray-Stewart$b Tracy$4auth$01309855 906 $aBOOK 912 $a9910367757003321 996 $aPolyamine Metabolism in Disease and Polyamine-Targeted Therapies$93029658 997 $aUNINA